Advertisement
Survey Series
For Advertisers
CONTENTS
May 2006
|
FEATURES | ||
|
How will one of the world's largest and most respected pharmaceutical companies come back?
By Fran Hawthorne Taking Stock of Merck Histones serve as slates to a dizzying array of modifications, but researchers are confident they can decipher the epigenetic puzzle.
By Brendan Maher Is It a Code: The Debate By Bryan M. Turner and Steven Henikoff |
 |
How to overcome the remaining hurdles in cell survival, supply, and immune rejection
By A.M. James Shapiro The Path to Clinical Protocols Less time, more conferences, and better mobile technology: Meeting planners struggle with the challenges facing the industry.
By Keith O'Brien What's the Value of Conferences? A Keystone Symposia survey says: $20-30 million in research fun savings By James W. Aiken |
ALSO THIS MONTH | |||
|
The industry needs more foxes and fewer hedgehogs.
By Richard Gallagher What went horribly wrong in a London clinical
Sex and the mind; Sex and the scientist; Sex and the flower; Sex and the coed
By Melissa Lee Phillips
By Ishani Ganguli
By Stephen Pincock
By Ishani Ganguli
By Ivan Oransky
TREATING GENETIC DISEASE TODAY Why wait until gene therapy and therapeutic cloning are perfected? Conventional treatments hold at least as much promise.
By Arnold Munnich My fellow columnist wants us to Google our brains. But will I lose my identity in the process?
By Glenn McGee Guess what? They're little and green!
By Jack Woodall Paul Nurse had trouble getting into graduate school. Twenty five years later, he won the Nobel Prize for his work on the cell cycle.
By Karen Hopkin SELDI-TOF still struggles to prove its worth as a clinical diagnostic tool
By Aileen Constans COPY NUMBER A MAJOR By Ishani Ganguli
WEBLOGO: DATA VISUALIZATION
By Jeffrey M. Perkel
A NEW WEAPON FOR
By Ishani Ganguli
|
 |
| |